Postponement of 'Meet Sanofi Management' event
Following the announcement on June 7, 2019 that Paul Hudson will succeed Olivier Brandicourt as Chief Executive Officer, Sanofi has decided to postpone the 'Meet Sanofi Management' event scheduled to take place on June 26. Sanofi regrets any inconvenience this may cause and intends to schedule an event in the first half of December.
Please contact the Sanofi IR team if you have any further queries related to this announcement.
At a glance
2019-06-07MMMM D, YYYY
Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
Communication from the Board of Directors
Stock market
Annual Report on Form 20-F 2018
Contact the Investor Relations team
54 rue La Boétie
75008 Paris FRANCE
France +33 (0)1 53 77 45 45 • ir@sanofi.com
United States +1 908 981 5560
In-depth reading
New franchise Rare Blood Disorders
In 2018, Sanofi created a leading platform in Rare Blood Disorders through a series of three strategic deals: we obtained global rights for fitusiran, acquired Bioverativ and Ablynx. These operations should expand Sanofi’s presence in Specialty Care and further strengthen our Research & Development pipeline.
The digital revolution
2018 Integrated Report
Quick links
About Sanofi
Individual shareholders
Access your dedicated section
Shareholder Handbook 2019
SANOFI IR The Investor Relations app
SANOFI IR provides financial information with direct access to key news, events, publications and a dedicated section for individual shareholders
